Human neural stem cells repress glioma cell progression in a paracrine manner by downregulating the Wnt/β-catenin signalling pathway.
conditioned medium
glioma
human neural stem cells
invasion
proliferation
Journal
FEBS open bio
ISSN: 2211-5463
Titre abrégé: FEBS Open Bio
Pays: England
ID NLM: 101580716
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
07
04
2023
received:
24
04
2022
accepted:
04
07
2023
medline:
5
9
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
Neural stem cells (NSCs) play crucial roles in neurological disorders and tissue injury repair through exerting paracrine effects. However, the effects of NSC-derived factors on glioma progression remain unclear. This study aimed to evaluate the effects of human NSC-conditioned medium (NSC-CM) on the behaviour of glioma cells using an in vitro co-culture system. Cell counting kit-8 and 5-ethynyl-2'-deoxyuridine assays revealed that NSC-CM inhibited glioma cell proliferation and growth in a fetal bovine serum (FBS)-independent manner. In addition, our wound-healing assay demonstrated that NSC-CM repressed glioma cell migration, while results from transwell and 3D spheroid invasion assays indicated that NSC-CM also reduced the invasion capacity of glioma cells. Flow cytometry showed that NSC-CM prevented cell cycle progression from the G1 to S phase and promoted apoptosis. Western blotting was used to show that the expression of Wnt/β-catenin pathway-related proteins, including β-catenin, c-Myc, cyclin D1, CD44 and Met, was remarkably decreased in NSC-CM-treated glioma cells. Furthermore, the addition of a Wnt/β-catenin pathway activator, CHIR99021, significantly induced the expression of β-catenin and Met and increased the proliferative and invasive capabilities of control medium-treated glioma cells but not those of NSC-CM-treated glioma cells. The use of enzyme-linked immunosorbent assays (ELISA) revealed the secretion of some antitumour factors in human and rat NSCs, including interferon-α and dickkopf-1. Our data suggest that NSC-CM partially inhibits glioma cell progression by downregulating Wnt/β-catenin signalling. This study may serve as a basis for developing future antiglioma therapies based on NSC derivatives.
Identifiants
pubmed: 37410396
doi: 10.1002/2211-5463.13671
pmc: PMC10476570
doi:
Substances chimiques
beta Catenin
0
Wnt Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1772-1788Informations de copyright
© 2023 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Nat Rev Cancer. 2002 Oct;2(10):764-76
pubmed: 12360279
Stem Cell Res Ther. 2016 Feb 09;7:25
pubmed: 26861734
Cancer Cell. 2011 Oct 18;20(4):427-42
pubmed: 22014570
Nat Rev Mol Cell Biol. 2005 Oct;6(10):777-88
pubmed: 16314867
J Neuroimmunol. 2021 Nov 15;360:577707
pubmed: 34507013
Biomicrofluidics. 2017 Jan 25;11(1):014106
pubmed: 28798841
Sci Transl Med. 2017 Feb 1;9(375):
pubmed: 28148846
Mol Cell Biochem. 2014 Jan;385(1-2):277-86
pubmed: 24104453
Stem Cell Res Ther. 2018 Aug 24;9(1):228
pubmed: 30143053
Neuro Oncol. 2012 Mar;14(3):256-65
pubmed: 22166262
Cancer Commun (Lond). 2021 Jul;41(7):576-595
pubmed: 34110104
Biomed Res Int. 2014;2014:109389
pubmed: 24971310
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Biosensors (Basel). 2021 Dec 09;11(12):
pubmed: 34940263
Adv Biosyst. 2020 Nov;4(11):e1900237
pubmed: 33245214
Cancer Biother Radiopharm. 2012 Nov;27(9):606-13
pubmed: 22917212
Exp Neurol. 2022 Sep;355:114142
pubmed: 35709983
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
pubmed: 33627401
Cancer Cell. 2009 Jan 6;15(1):45-56
pubmed: 19111880
Biomed Pharmacother. 2020 Dec;132:110851
pubmed: 33080466
Cell Transplant. 2017 Mar 13;26(3):469-482
pubmed: 27737726
CNS Oncol. 2021 Jun 1;10(2):CNS73
pubmed: 34006134
Curr Biol. 2001 Jun 26;11(12):951-61
pubmed: 11448771
Oncotarget. 2017 Aug 14;8(44):76949-76960
pubmed: 29100360
Cancer Gene Ther. 2009 Apr;16(4):351-61
pubmed: 18949017
Cancer Res. 2012 Nov 15;72(22):5658-62
pubmed: 23139209
Mol Biol Rep. 2019 Apr;46(2):1693-1700
pubmed: 30737617
J Clin Neurosci. 2009 Dec;16(12):1619-23
pubmed: 19836246
Int J Biol Sci. 2022 Oct 3;18(15):5943-5962
pubmed: 36263177
Stem Cells Int. 2016;2016:1890568
pubmed: 27579042
Cancer Discov. 2021 Oct;11(10):2413-2429
pubmed: 34518209
Endocrinology. 2004 Dec;145(12):5439-47
pubmed: 15331580
Stem Cells Transl Med. 2018 Oct;7(10):740-747
pubmed: 30133188
Cell. 2011 Jul 22;146(2):209-21
pubmed: 21737130
Stem Cells Dev. 2020 Aug;29(16):1084-1095
pubmed: 32560594
Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):10013-10023
pubmed: 31799671
Breast Cancer Res Treat. 2010 Nov;124(2):317-26
pubmed: 20087650
EBioMedicine. 2022 Jan;75:103756
pubmed: 34942444
Front Cell Neurosci. 2021 Jan 28;14:612560
pubmed: 33584205
Hum Cell. 2019 Apr;32(2):88-94
pubmed: 30730038
Nature. 2018 Aug;560(7717):243-247
pubmed: 30069053
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Cell Mol Biol (Noisy-le-grand). 2016 Oct 31;62(12):68-73
pubmed: 27894403
Cancer Res. 2011 Apr 15;71(8):3066-75
pubmed: 21363911
J Surg Oncol. 2002 Jan;79(1):30-5; discussion 35-6
pubmed: 11754374
Neural Regen Res. 2022 Oct;17(10):2260-2266
pubmed: 35259847
Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4836-41
pubmed: 27044087
Cell Transplant. 2014;23 Suppl 1:S45-56
pubmed: 25333841
Int J Oncol. 2022 Oct;61(4):
pubmed: 35929514
Cell Mol Life Sci. 2022 Mar 16;79(3):191
pubmed: 35292881
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
pubmed: 14685170
Methods. 2016 Apr 15;99:37-43
pubmed: 26314280
Clin Transl Oncol. 2019 Nov;21(11):1551-1560
pubmed: 30945128
J Cell Biochem. 2019 Apr;120(4):5472-5479
pubmed: 30367517
Biochem Pharmacol. 2017 Oct 1;141:77-85
pubmed: 28625813
Cancer Res. 2006 Mar 1;66(5):2630-8
pubmed: 16510582
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945
Cancer Res. 2002 Sep 15;62(18):5126-8
pubmed: 12234972